HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 5, Pages 1169-1178
Publisher
Springer Nature
Online
2014-02-12
DOI
10.1038/bjc.2014.61
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance
- (2013) W. Q. Sheng et al. ANNALS OF ONCOLOGY
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
- (2013) Ling Shan et al. Diagnostic Pathology
- Molecular Profiling of Gastric Cancer: Toward Personalized Cancer Medicine
- (2013) Lincoln D. Nadauld et al. JOURNAL OF CLINICAL ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
- (2012) G Minuti et al. BRITISH JOURNAL OF CANCER
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
- (2012) Cristina Oliveras-Ferraros et al. CELL CYCLE
- Advanced HER2-positive gastric cancer: Current and future targeted therapies
- (2012) Roberto A. Pazo Cid et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- New targeted therapies for gastric cancer
- (2011) Yoshinari Asaoka et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
- (2011) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I and II Clinical Trials for Gastric Cancer
- (2011) Nikhil I. Khushalani Surgical Oncology Clinics of North America
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Advanced gastric cancer – Slow but steady progress
- (2010) Derek G. Power et al. CANCER TREATMENT REVIEWS
- Early oncology clinical trial design in the era of molecular-targeted agents
- (2010) Andre T Brunetto et al. Future Oncology
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors
- (2009) Sergei L. Timofeevski et al. BIOCHEMISTRY
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More